My watch list  

Most therapeutics in development for NASH target specific enzymes or receptors that regulate NASH. Cirius is taking a different approach and developing a new class of drugs that work by rebalancing metabolism at its root – through balancing mitochondrial metabolism. MSDC-0602K has the potential to reduce the impact of conditions that produce the metabolic dysregulation that drives insulin resistance and tissue damage.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE